Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: Effect on lung and systemic decorporation of plutonium

Gervelas, C.; Sérandour, Anne-Laure; Geiger, Sandrine; Grillon, G.; Fritsch, P.; Taulelle, C.; Gall, B. Le; Bénech, Henri; Deverre, Jean-Robert; Fattal, Elias; Tsapis, Nicolas

doi:10.1016/j.jconrel.2006.11.027

Cited by 70 publications

(43 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The insufflator has been used to deliver different powders from nanoparticles [89] to large porous particles [90,91]. The physicochemical characteristics of the powder, including particle size distribution, as measured by a variety of techniques have been reported to be essentially unaffected by passage through the device [67,90,92,89,93,94]. However, the position of the device in the trachea of the animal during powder delivery may affect the percentage of powder deposited in the different lung lobes [95].…”

Section: Direct Administration Methodsmentioning

confidence: 99%

In vivo animal models for drug delivery across the lung mucosal barrier☆

Cryan

Sivadas

García-Contreras

2007

Advanced Drug Delivery Reviews

130

View full text Add to dashboard Cite

Section: Direct Administration Methodsmentioning

confidence: 99%

In vivo animal models for drug delivery across the lung mucosal barrier☆

Cryan

Sivadas

García-Contreras

2007

Advanced Drug Delivery Reviews

130

View full text Add to dashboard Cite

“…This decrease in aggregation can be explained by the surface roughness, which decreases the forces existing between the particles. 16,45 Earlier studies of dexamethasone encapsulation showed that changes in particle size distribution can be due to particle aggregation, such that both the mean and median sizes increased steeply as more dexamethasone was incorporated into the formulation, with the size increase being greater at higher dexamethasone concentrations. 29 The zeta potential for all formulations was found to be negative, from -48 to -35 mV, with the zeta potential becoming less negative as the concentration of methylprednisolone increased, possibly because of the contribution to neutrality provided by the active principle.…”

Section: Encapsulation Efficiency For Methylprednisolonementioning

confidence: 99%

Development of biodegradable methylprednisolone microparticles for treatment of articular pathology using a spray-drying technique

Tobar-Grande¹,

Godoy²,

Bustos³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:In this work, microparticles were prepared by spray-drying using albumin, chondroitin sulfate, and hyaluronic acid as excipients to create a controlled-release methylprednisolone system for use in inflammatory disorders such as arthritis. Scanning electron microscopy demonstrated that these microparticles were almost spherical, with development of surface wrinkling as the methylprednisolone load in the formulation was increased. The methylprednisolone load also had a direct influence on the mean diameter and zeta potential of the microparticles. Interactions between formulation excipients and the active drug were evaluated by x-ray diffraction, differential scanning calorimetry, and thermal gravimetric analysis, showing limited amounts of methylprednisolone in a crystalline state in the loaded microparticles. The encapsulation efficiency of methylprednisolone was approximately 89% in all formulations. The rate of methylprednisolone release from the microparticles depended on the initial drug load in the formulation. In vitro cytotoxic evaluation using THP-1 cells showed that none of the formulations prepared triggered an inflammatory response on release of interleukin-1β, nor did they affect cellular viability, except for the 9.1% methylprednisolone formulation, which was the maximum test concentration used. The microparticles developed in this study have characteristics amenable to a therapeutic role in inflammatory pathology, such as arthritis.

show abstract

“…Previous research has shown that ammonium bicarbonate (NH 4 HCO 3 ) sublimes above 50°C and removed directly during spray drying [8]. This property of NH 4 HCO 3 as a pore former was also termed the 'baking powder effect' whereby the material leaves voids in formulated particles due to evolution of H 2 O↑, NH 3 ↑ and CO 2 ↑ [9].…”

Section: Introductionmentioning

confidence: 99%

A pragmatic approach for engineering porous mannitol and mechanistic evaluation of particle performance

Al-Khattawi

Koner

Rue

et al. 2015

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

The importance of mannitol has increased recently as an emerging diluent for orodispersible dosage forms. The study aims to prepare spray dried mannitol retaining high porosity and mechanical strength for the development of orally disintegrating tablets (ODTs).Aqueous feed of D-mannitol (10% w/v) comprising ammonium bicarbonate, NH 4 HCO 3 (5% w/v) as pore former was spray dried at inlet temperature of 110-170°C. Compacts were prepared at 20 kN and characterized for porosity, hardness and disintegration time. Particle morphology and drying mechanisms were studied using thermal (HSM, DSC and TGA) and polymorphic (XRD) methods.Tablet porosity increased from 0.20 ± 0.002 for pure mannitol to 0.53 ± 0.03 using fabricated porous mannitol. Disintegration time dropped by 50-77% from 135 ± 5.29 sec for pure mannitol to 75.33 ± 2.52 -31.67 ± 1.53 sec for mannitol 110 -170°C. Hardness increased by 150% at 110°C (258.67 ± 28.89 N) and 30% at 150°C (152.70 ± 10.58 N) compared to pure mannitol tablets (104.17 ± 1.70 N). Increasing inlet temperature resulted in reducing tablet hardness due to generation of 'micro-sponge'-like particles exhibiting significant elastic recovery. Impact of mannitol polymorphism on plasticity/elasticity cannot be ruled out as a mixture of α and β polymorphs formed upon spray drying.

show abstract

Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: Effect on lung and systemic decorporation of plutonium

Cited by 70 publications

References 30 publications

In vivo animal models for drug delivery across the lung mucosal barrier☆

In vivo animal models for drug delivery across the lung mucosal barrier☆

Development of biodegradable methylprednisolone microparticles for treatment of articular pathology using a spray-drying technique

A pragmatic approach for engineering porous mannitol and mechanistic evaluation of particle performance

Contact Info

Product

Resources

About